RBC Capital reiterates Axsome Therapeutics stock rating at Outperform

RBC Capital reiterated Outperform on Axsome Therapeutics with a $295 price target, arguing the shares—down about 28% in the past month versus a 6% decline in the XBI—are dislocated from fair value and that recent prescription softness reflects seasonality and sampling. RBC sees a $2.3 billion Alzheimer’s disease agitation opportunity in 2035 and said lower expectations ahead of the quarter are beatable. Axsome reported Q2 2026 revenue of $218.4 million, above H.C. Wainwright’s $211.1 million forecast, while its $0.99-per-share net loss matched expectations; other firms reiterated or initiated Buy ratings with targets of $285–$316.

Analysis

The actionable signal is AXSM, not ASML—the headline and body do not match. The selloff creates a potential setup, but the bullish case currently leans on management/analyst interpretation of prescription softness as seasonality and sampling. Those explanations need independent confirmation: reported revenue can lag trialing and sampling, while sustained weak refill or new-start trends would indicate a real adoption problem. A distant market-size estimate should not anchor near-term valuation.

In the next 1–3 months, prescription trajectory, payer access, and management’s explanation of new starts versus refills matter more than additional broker target changes. Over 6–18 months, Auvelity’s commercial execution must demonstrate repeat prescribing and a durable contribution to growth. Rexulti (Otsuka/Lundbeck) and non-drug care pathways are relevant alternatives; weak adoption could also constrain expectations for the broader launch opportunity. The reported quarterly revenue beat is supportive but does not by itself establish launch quality, especially with a continuing loss per share.

Contrarian view: the drawdown may over-discount a noisy early launch, but the oversold reading and analyst enthusiasm are not evidence of a trough. Prefer staged exposure rather than buying the full dip. Falsify the recovery thesis if subsequent prescription data fail to improve, refills remain weak, or guidance is reduced; strengthen it if new starts and refills accelerate together and revenue conversion follows.

Key Decisions for Investors

• AXSM: Consider a small, staged long only for portfolios able to tolerate biotech volatility; add after independently sourced prescription data confirm improving new starts and refills. Do not underwrite the position solely to broker price targets or the long-dated market estimate.
• For a defined-risk expression, evaluate a call spread rather than outright calls, sized to the next prescription/earnings catalyst; avoid paying for volatility before checking option pricing and event timing.
• Track weekly or monthly prescription measures, new starts versus refills, payer coverage, sampling effects, and management guidance. A cut to launch expectations or another period of deteriorating refill trends is a thesis break and a reason to exit/reassess.
• No actionable read-through to ASML, MFG, TFC, or WFC: the article body concerns AXSM, and the headline appears mismatched.